FDA's Gottlieb Aims To End Biosimilars Groundhog Day.
The FDA commissioner has an 11-step "action plan" to get biosimilars out of a repeat mode of unrealized potential. But issues like interchangeability still need clarifying if biosimilars are to have a major effect on drug expenditures.